https://www.nasdaq.com/press-release/aptorum-group-limited-announces-results-of-2021-annual-general-meeting-of
https://www.nasdaq.com/press-release/aptorum-group-limited-to-hold-annual-general-meeting-of-shareholders-on-december-2
https://www.nasdaq.com/press-release/aptorum-group-limited-interview-to-air-on-bloomberg-u.s.-2021-10-15
https://www.nasdaq.com/press-release/aptorum-group-limited-has-received-ind-clearance-from-the-us-fda-to-initiate-clinical
https://www.nasdaq.com/press-release/aptorum-group-limited-reports-financial-results-and-business-update-for-the-six-2
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-interim-results-of-the-phase-1-clinical
https://www.nasdaq.com/press-release/aptorum-group-interview-to-air-on-bloomberg-television-u.s.-on-the-redchip-money
https://www.nasdaq.com/press-release/aptorum-group-ceo-subscribed-shares-in-the-company-2021-05-26
https://www.nasdaq.com/press-release/aptorum-group-announces-positive-interim-phase-i-clinical-trial-progress-for-als-4
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-benzinga-global-small-cap-conference-2021-05
https://www.nasdaq.com/press-release/aptorum-group-enters-into-an-agreement-with-exeltis-to-develop-aptorums-novel
https://www.nasdaq.com/press-release/aptorum-group-limited-interview-to-air-on-bloomberg-television-u.s.-on-the-redchip
https://www.nasdaq.com/press-release/aptorum-group-enters-into-material-transfer-and-exclusive-option-to-license-agreement
https://www.nasdaq.com/press-release/aptorum-group-limited-reports-2020-fiscal-year-end-financial-results-and-provides
https://www.nasdaq.com/press-release/aptorum-group-announces-dosing-first-human-subject-in-a-phase-i-clinical-trial-of-als
https://www.nasdaq.com/press-release/aptorum-group-receives-clearance-from-health-canada-to-initiate-a-phase-1-clinical
https://www.nasdaq.com/press-release/aptorum-group-announces-submission-of-clinical-trial-application-for-als-4-an-orally
https://www.nasdaq.com/press-release/aptorum-group-limited-announces-results-of-2020-annual-general-meeting-of
https://www.nasdaq.com/press-release/aptorum-group-limited-to-hold-annual-general-meeting-of-shareholders-on-december-9
https://www.nasdaq.com/press-release/aptorum-group-announces-closing-of-%249.0-million-public-offering-2020-10-02
https://www.nasdaq.com/press-release/aptorum-group-announces-pricing-of-%249.0-million-public-offering-2020-09-29
https://www.nasdaq.com/press-release/aptorum-group-launches-infectious-disease-liquid-biopsy-subsidiary-start-up-and
https://www.nasdaq.com/press-release/aptorum-group-launches-infectious-disease-liquid-biopsy-subsidiary-start-up-and-0
https://www.nasdaq.com/press-release/aptorum-group-to-hold-investor-webinar-and-present-at-the-wall-street-investor-forum
https://www.nasdaq.com/press-release/aptorum-group-to-hold-investor-webinar-and-present-at-the-wall-street-investor-0
https://www.nasdaq.com/press-release/aptorum-group-joins-the-beam-alliance-to-combat-antimicrobial-resistance-2020-09-08-0
https://www.nasdaq.com/press-release/aptorum-group-joins-the-beam-alliance-to-combat-antimicrobial-resistance-2020-09-08
https://www.nasdaq.com/press-release/aptorum-group-announces-video-update-discussing-positive-data-on-sact-1-against
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-on-als-4-against-mrsa-wound-infection-0
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-on-sact-1-against-neuroblastoma-and-0
https://www.nasdaq.com/press-release/aptorum-group-limited-reports-financial-results-and-business-update-for-the-six-1
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-on-als-4-against-mrsa-wound-infection
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-on-sact-1-against-neuroblastoma-and
https://www.nasdaq.com/press-release/aptorum-group-limited-reports-financial-results-and-business-update-for-the-six-0
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/aptorum-group-interview-to-air-on-bloomberg-international-on-the-redchip-money-0
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-ld-500-virtual-conference-2020-08-26
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-ld-500-virtual-conference-and-h.c.-wainwright
https://www.nasdaq.com/press-release/aptorum-group-appoints-dr.-herman-weiss-as-ceo-of-microbiome-based-platform-claves
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/aptorum-group-becomes-the-first-nasdaq-listed-biopharmaceutical-company-admitted-to-0
https://www.nasdaq.com/press-release/aptorum-group-becomes-the-first-nasdaq-listed-biopharmaceutical-company-admitted-to
https://www.nasdaq.com/press-release/aptorum-group-prospectus-receives-approval-for-listing-on-the-euronext-paris-stock
https://www.nasdaq.com/press-release/aptorum-group-limited-strengthens-its-presence-in-the-us-with-the-appointment-of-dr.
https://www.nasdaq.com/press-release/aptorum-group-interview-to-air-on-bloomberg-international-on-the-redchip-money-report
https://www.nasdaq.com/press-release/aptorum-group-to-hold-investor-webinar-and-qa-session-with-president-on-may-19-2020
https://www.nasdaq.com/press-release/aptorum-group-limited-reports-2019-fiscal-year-end-financial-results-and-provides
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-infectious-disease-virtual-conference-2020-04
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-planet-microcap-showcase-virtual-investor
https://www.nasdaq.com/press-release/aptorum-group-collaborates-with-covar-pharmaceuticals-to-investigate-at-least-3-0
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-solebury-trout-virtual-investor-conference-0
https://www.nasdaq.com/press-release/aptorum-group-limited-corporate-update-and-to-hold-q1-2020-investor-update-call-to-0
https://www.nasdaq.com/press-release/aptorum-group-limited-to-present-at-the-solebury-trout-virtual-investor-conference
https://www.nasdaq.com/press-release/aptorum-group-limited-corporate-update-and-to-hold-q1-2020-investor-update-call-to
https://www.nasdaq.com/press-release/aptorum-group-collaborates-with-covar-pharmaceuticals-to-investigate-at-least-3
https://www.nasdaq.com/press-release/aptorum-group-announces-closing-of-%2410-million-registered-direct-offering-of-class-a
https://www.nasdaq.com/press-release/aptorum-group-announces-pricing-of-%2410-million-registered-direct-offering-2020-02-26
https://www.nasdaq.com/press-release/aptorum-group-commences-commercialization-of-dioscorea-opposita-bioactive-0
https://www.nasdaq.com/press-release/aptorum-group-commences-commercialization-of-dioscorea-opposita-bioactive
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-for-its-als-4-small-molecule-anti-0
https://www.nasdaq.com/press-release/aptorum-group-announces-significant-progress-of-repurposed-drug-candidate-sact-1-0
https://www.nasdaq.com/press-release/aptorum-group-announces-significant-progress-of-repurposed-drug-candidate-sact-1-for
https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-data-for-its-als-4-small-molecule-anti
https://www.nasdaq.com/press-release/aptorum-group-limited-announces-results-of-2019-annual-general-meeting-2019-11-15
https://www.nasdaq.com/press-release/aptorum-group-has-initiated-ind-enabling-studies-for-its-als-4-small-molecule-0
https://www.nasdaq.com/press-release/aptorum-group-announces-the-development-of-microbiome-drug-candidate-targeting-0
https://www.nasdaq.com/press-release/aptorum-group-oznamuje-vyvoj-mikrobiomoveho-kandidata-na-lek-urceny-k-lecbe-obezity-a
https://www.nasdaq.com/press-release/aptorum-group-announces-the-development-of-microbiome-drug-candidate-targeting
